Multifocal Motor Neuropathy Market
Number of pages: 100 | Report Format: PDF | Published date: April 26, 2023
Historical Years – 2021 | Base Year – 2022 | Forecasted Years – 2023-2031
|
Report Attribute |
Details |
|
CAGR |
3.6% |
|
Base Year for Estimation |
2022 |
|
Forecast Period |
2023 to 2031 |
|
Historical Year |
2021 |
|
Segments Covered |
Drug Type, End user, and Region. |
|
Regional Scope |
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa |
According to the deep-dive market assessment study by Growth Plus Reports, global multifocal motor neuropathy is expected to register a revenue CAGR of 3.6% during the forecast period.
Multifocal Motor Neuropathy Market Fundamentals
Multifocal motor neuropathy (MMN), also known as multifocal motor neuropathy with conduction block (MMNCB), is an uncommon, acquired motor neuropathy characterized by gradual asymmetric weakening and no sensory abnormalities. It usually affects the upper limbs more than the lower limbs. Electrodiagnostic investigations frequently show asymmetric motor neuropathy with a distinctive conduction block. The majority of patients have serum IgM anti-ganglioside antibodies (anti-GM1).
MMN often manifests as an asymmetrical upper limb pure motor multiple mononeuropathy with significant wasting despite a brief history of weakness. Males are more typically affected by MMN, with a male-to-female ratio of 2.7:1. The age at symptom onset might range from 20 to 70 years, with a mean of 40 years. The first sign is often distal upper limb weakness, with finger flexors remaining relatively unaffected. In one-third of patients, foot drops are the initial symptom. Many people who have lower limb involvement eventually acquire upper limb problems. The involvement of the non-dominant upper limb is more common. Fasciculations and cramps are common, affecting up to 40% of patients, and can cause local muscular hypertrophy in some situations.
Immune-mediated motor neuropathy is characterized by multifocal motor neuropathy. This is supported by a high incidence of serum IgM anti-GM1 antibodies in these individuals and a positive response to IVIG. The higher concentration of GM1 in motor nerve myelin than sensory nerve myelin may explain the typical motor involvement in MMN.
Multifocal motor neuropathy is an uncommon illness, with a global frequency of fewer than one in 100,000 persons. The reported frequency of MMN per 100,000 individuals in Austria is 0.65 and 0.29 in Japan. It is 2.7 times more frequent in men than in women. Furthermore, the condition is diagnosed, particularly in people in their third to fifth decades, however, it has also been recorded in children as young as six years old and the elderly. There are currently no effective therapies for preventing this condition. Educating patients about the disease's diagnosis and natural history is critical. Most patients will require long-term IVIg and SCIg therapies, which can be expensive and have unintended side effects. Despite consistent therapy, the condition can worsen, although it is usually not deadly.
Nerve ultrasonography (US) and magnetic resonance imaging (MRI) can provide valuable diagnostic information, particularly when electrophysiological tests are inconclusive. When conduction blockages are not evident, or there is severe axonal degeneration, MMN diagnosis might be difficult. In almost half of the patients with MMN and CIDP, spinal MRI may exhibit T2 hyperintense signals in the brachial plexus with or without contrast enhancement. These signals are asymmetric and frequently unilateral in MMN but bilateral and symmetrical in CIDP.
Multifocal Motor Neuropathy Market Dynamics
Globally, it has seen a large increase in the frequency of rare diseases. This trend is expected to dramatically increase demand for treatment in the future, as incidences of multifocal motor neuropathy are increasing rapidly worldwide. Growing emphasis on health, rising investments in medical research, rising healthcare expenditure, growing awareness of motor neuropathy, poor lifestyle habits, high obesity incidence, and an aging population are key factors that could drive demand for nerve treatment products and therapies over the forecast period.
The increased availability of management therapy drugs is expected to generate profitable development prospects for both existing and emerging drug producers in the future. The major pharmacological therapy option for MMNCB is the use of IVIg. It is worth noting that more than three-quarters of the patients react to IVIG. Muscle strength improves as a result of the treatment. Advances in research and development are expected to boost demand for improved treatment methods like infrared therapy for multifocal motor neuropathy in the future.
ALS, CIDP, and hereditary neuropathy with pressure palsies (HNPP) are relevant differential diagnosis for multifocal motor neuropathy. Radiculopathy, entrapment neuropathies, mononeuritis multiplex, inherited motor neuropathies, porphyria, and lead toxicity are among the possible diagnoses to examine. Multifocal motor neuropathy typically has a favorable prognosis. Approximately 80% of patients benefit from IVIG therapy. About 20% of patients achieve long-term remission, while the remainder requires IVIG or SCIG treatments on a regular basis. Even among non-responders, muscular weakening advances slowly, and the majority of patients can conduct everyday tasks. In one research, more than 94% of participants remained in their jobs.
Multifocal Motor Neuropathy Market Ecosystem
The global multifocal motor neuropathy market is analyzed from the following perspectives by drug type, distribution channel, and region.
Multifocal Motor Neuropathy Market by Drug Type
[75464]
Based on the drug type, the global multifocal motor neuropathy market is segmented into gammagard liquid, cyclophosphamide, mycophenolate mofetil, azathioprine, rituximab, and others.
The gammagard liquid is likely to dominate the market during the forecast period. This drug replaces primary humoral immunodeficiency (PI) in adults and children two years and older. Indicated as a maintenance treatment in adult patients with Multifocal Motor Neuropathy (MMN) to enhance muscular strength and impairment. With the launch of GAMMAGARD LIQUID as an FDA-approved therapeutic option, patients now have a proven medication to enhance their hand and foot function. The regulatory clearance of GAMMAGARD LIQUID for treating MMN is a significant milestone for the firm as it continues to strengthen its position in the immunoglobulin industry and expands into rare neurology illnesses. GAMMAGARD provides individuals with MMN with a therapy alternative that has been carefully investigated and utilized for many years in primary immunodeficiency patients.
Various immunomodulatory drugs, including cyclophosphamide, mycophenolate mofetil, azathioprine, and rituximab, have been studied with varying degrees of effectiveness. Although oral cyclophosphamide has been shown to be successful in maintaining illness remission and lowering IGIg frequency, it has substantial side effects.
Multifocal Motor Neuropathy Market by Distribution Channel
Based on the distribution channel, the global multifocal motor neuropathy market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.
The hospital pharmacy is likely to dominate the market during the forecast period. The presence of modern healthcare infrastructure and round-the-clock observation by healthcare experts are two main factors for the segment's dominance. Aside from that, a rising number of hospital settings in industrialized and developing countries are developing to the healthcare requirements of the general public, resulting in an increase in inpatient admissions.
The retail pharmacies segment is predicted to be the second-largest market segment, owing to increased product delivery to hospitals and partnerships with various medical practitioners, clinics, and others. Online pharmacies are also expected to grow rapidly due to the simplicity with which people may obtain medications from the comfort of their own homes.
Multifocal Motor Neuropathy Market by Region
The global multifocal motor neuropathy market is segmented based on region: North America, Europe, Asia Pacific, Latin America, and Middle East & Africa.
North America is likely to dominate the market during the forecast period due to the increasing activities by different government agencies to promote the development of new drugs, which are likely to help market growth during the forecast period. The development of IVIG necessitates a well-developed manufacturing facility and significant capital inputs, resulting in a high final product cost. As a result, this issue is expected to limit market growth. Furthermore, IVIG products are subject to severe safety and handling standards, projected to impede market expansion.
Europe region showed significant growth due to a rise in the prevalence of multifocal motor neuropathy the prevalence, as Austria has a slightly higher prevalence than Japan (0.29), but comparable to European results, where a prevalence/100000 of 0.5 was observed from Southeast England and 0.6 from the Netherlands. However, the true incidence in these nations may be significantly greater because some patients were not reported, and others were not diagnosed.
Due to increased healthcare reforms, government attempts to give costly IG treatments cheaply, and rising healthcare spending, Asia Pacific is predicted to expand at the fastest CAGR throughout the forecast period. Immunoglobulin consumption per person is substantially lower in nations such as Japan, India, and other Southeast Asian countries. However, the growing number of patients with immunodeficiencies and the availability of reimbursement for these treatments are expected to increase demand throughout the projection period.
During the research period, Latin America, the Middle East, and Africa are expected to increase at a modest CAGR. Rising rare disease awareness, a growing number of healthcare professionals interested in this therapy, and more product availability in these locations are all projected to boost demand during the forecast period.
Multifocal Motor Neuropathy Competitive Landscape
This is influencing major market players to broaden their product portfolio globally. As a result, the diverse product portfolio of key players tends to generate revenue for the company. In terms of revenue, Takeda Pharmaceutical Company Limited dominates due to blockbuster products such as GAMMAGARD LIQUID.
The significant upgrading of the product globally is expected to fuel market growth during the forecast period. Some of the prominent market players in the global multifocal motor neuropathy market include,
Multifocal Motor Neuropathy Strategic Developments
Multifocal motor neuropathy (MMN), also known as multifocal motor neuropathy with conduction block (MMNCB), is an uncommon, acquired motor neuropathy characterized by gradual asymmetric weakening and no sensory abnormalities. It usually affects the upper limbs more than the lower limbs.
North America is the key growth region in the global multifocal motor neuropathy market.
The rising prevalence of rare diseases and rising research and development in the market are the prime driving factors.
The GAMMAGARD LIQUID drug type segment is driving the market.
Some prominent market players in the global multifocal motor neuropathy market include Takeda Pharmaceutical Company Limited, Cadila Pharmaceuticals Ltd., and Genentech.
*Insights on financial performance are subject to the availability of information in the public domain